問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱倫瑋

Recruiting

List

28Cases

2020-05-18 - 2023-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-04-04 - 2029-12-07

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-04-01 - 2033-01-20

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-03-01 - 2028-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-11-30 - 2027-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-03-01 - 2030-07-16

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-01-23 - 2027-10-13

Phase I

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2018-01-31 - 2026-02-08

Phase III

A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA

  • Condition/Disease

    Acute Myeloid Leukemia, AML

  • Test Drug

    Glasdegib (PF-04449913)

Participate Sites
5Sites

Recruiting5Sites

高志平
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB